Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease.
Regina M OndrasikLeanne J CookCorey A SiegelGregory J TsongalisWahab A KhanPublished in: American journal of clinical pathology (2023)
Here we present validation of a lab-developed test for a rapid HLA-DQA1*05 (rs2097432) pharmacogenomics assay targeting a hotspot identified by genome-wide association studies. Targeted genotyping employed here will allow for expeditious personalized therapeutic selection.
Keyphrases
- patients with inflammatory bowel disease
- high throughput
- genome wide association
- cancer therapy
- loop mediated isothermal amplification
- clinical decision support
- adverse drug
- rheumatoid arthritis
- genome wide
- dna methylation
- stem cells
- gene expression
- case control
- mesenchymal stem cells
- sensitive detection
- cell therapy
- electronic health record